Latest Hemarthrosis Stories
A Rush University Medical Center led international research team has announced that a treatment to prevent bleeding episodes in children with hemophilia A also is effective for adolescents and adults.
A new drug commonly used to treat bleeding events in people with severe hemophilia can also be used to prevent such events from happening at all, according to this study.
An international research team led by Dr. Cindy Leissinger of Tulane University School of Medicine, along with Dr. Alessandro Gringeri from the University of Milan, has found that a drug commonly used to treat bleeding events in people with a type of severe hemophilia can also be used to prevent such events from happening in the first place.
CHICAGO and HOBOKEN, N.J., Aug. 2 /PRNewswire/ -- Octapharma USA today announced the first grant recipient of the Octapharma 25th Anniversary Grants Program is the Rush Hemophilia & Thrombophilia Center at Rush University Medical Center.
Bayer HealthCare has announced that the FDA has approved routine prophylaxis with Kogenate FS Antihemophilic Factor to reduce the frequency of bleeding episodes and the risk of joint damage in patients aged 0-16 years with severe hemophilia A with no pre-existing joint damage.